189 related articles for article (PubMed ID: 29955143)
1. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.
Auguste A; Genestie C; De Bruyn M; Adam J; Le Formal A; Drusch F; Pautier P; Crosbie EJ; MacKay H; Kitchener HC; Powell M; Pollock PM; Mileshkin L; Edmondson RJ; Nout R; Nijman HW; Creutzberg CL; Bosse T; Leary A
Mod Pathol; 2018 Dec; 31(12):1851-1861. PubMed ID: 29955143
[TBL] [Abstract][Full Text] [Related]
2. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Stelloo E; Bosse T; Nout RA; MacKay HJ; Church DN; Nijman HW; Leary A; Edmondson RJ; Powell ME; Crosbie EJ; Kitchener HC; Mileshkin L; Pollock PM; Smit VT; Creutzberg CL
Mod Pathol; 2015 Jun; 28(6):836-44. PubMed ID: 25720322
[TBL] [Abstract][Full Text] [Related]
3. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
4. Immunologic Signatures across Molecular Subtypes and Potential Biomarkers for Sub-Stratification in Endometrial Cancer.
Jiang F; Jiang S; Cao D; Mao M; Xiang Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675305
[TBL] [Abstract][Full Text] [Related]
5. Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study.
Dai Y; Zhao L; Hua D; Cui L; Zhang X; Kang N; Qu L; Li L; Li H; Shen D; Wang Z; Wang J
Front Immunol; 2022; 13():1035616. PubMed ID: 36532042
[TBL] [Abstract][Full Text] [Related]
6. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
7. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
Fremond S; Andani S; Barkey Wolf J; Dijkstra J; Melsbach S; Jobsen JJ; Brinkhuis M; Roothaan S; Jurgenliemk-Schulz I; Lutgens LCHW; Nout RA; van der Steen-Banasik EM; de Boer SM; Powell ME; Singh N; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Smit VTHBM; Creutzberg CL; Horeweg N; Koelzer VH; Bosse T
Lancet Digit Health; 2023 Feb; 5(2):e71-e82. PubMed ID: 36496303
[TBL] [Abstract][Full Text] [Related]
8. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P; MacKay HJ; Powell ME; Bosse T; Creutzberg CL; Kitchener HC
Gynecol Oncol; 2017 Aug; 146(2):327-333. PubMed ID: 28511869
[TBL] [Abstract][Full Text] [Related]
9. Reclassifying endometrial carcinomas with a combined morphological and molecular approach.
Carlson J; McCluggage WG
Curr Opin Oncol; 2019 Sep; 31(5):411-419. PubMed ID: 31261170
[TBL] [Abstract][Full Text] [Related]
10. Immunological profiling of molecularly classified high-risk endometrial cancers identifies
Eggink FA; Van Gool IC; Leary A; Pollock PM; Crosbie EJ; Mileshkin L; Jordanova ES; Adam J; Freeman-Mills L; Church DN; Creutzberg CL; De Bruyn M; Nijman HW; Bosse T
Oncoimmunology; 2017; 6(2):e1264565. PubMed ID: 28344870
[TBL] [Abstract][Full Text] [Related]
11. TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma.
Travaglino A; Raffone A; Gencarelli A; Mollo A; Guida M; Insabato L; Santoro A; Zannoni GF; Zullo F
Pathol Oncol Res; 2020 Oct; 26(4):2067-2073. PubMed ID: 32472441
[TBL] [Abstract][Full Text] [Related]
12. Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology.
Akhtar M; Al Hyassat S; Elaiwy O; Rashid S; Al-Nabet ADMH
Adv Anat Pathol; 2019 Nov; 26(6):421-427. PubMed ID: 31567131
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer.
Beinse G; Le Frere Belda MA; Just PA; Bekmezian N; Koual M; Garinet S; Leroy K; Letourneur F; Lusson A; Mulot C; Le Corre D; Metairie M; Delanoy N; Blons H; Gervais C; Durdux C; Chapron C; Goldwasser F; Terris B; Badoual C; Taly V; Laurent-Puig P; Borghese B; Bats AS; Alexandre J
Gynecol Oncol; 2022 Mar; 164(3):596-606. PubMed ID: 35033379
[TBL] [Abstract][Full Text] [Related]
15. Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas.
Pain FA; Beinse G; Azaïs H; Auvray-Kuentz M; Garcin LM; Delanoy N; Bentivegna E; Benoit L; Nguyen-Xuan HT; Blons H; Fabiano E; LE Frère Belda MA; Bats AS; Koual M
Eur J Surg Oncol; 2023 Sep; 49(9):106954. PubMed ID: 37349159
[TBL] [Abstract][Full Text] [Related]
16. [Application and clinical significance of TCGA molecular classification in endometrial cancer].
Zhao LY; Dai YB; Li LW; Wang ZQ; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2021 Oct; 56(10):697-704. PubMed ID: 34823319
[No Abstract] [Full Text] [Related]
17. [Histological and molecular classification of endometrial carcinoma and therapeutical implications].
Genestie C; Leary A; Devouassoux M; Auguste A
Bull Cancer; 2017 Dec; 104(12):1001-1012. PubMed ID: 29031505
[TBL] [Abstract][Full Text] [Related]
18. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups.
Rau TT; Bettschen E; Büchi C; Christe L; Rohner A; Müller MD; Carlson JW; Imboden S; Zlobec I
Mod Pathol; 2021 Jan; 34(1):222-232. PubMed ID: 32728223
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
